Views

CrossRef citations to date

Altmetric

Letters to the Editor

Allogeneic hematopoietic cell transplantation using non-myeloablative ATG/TLI conditioning for lymphomas

Tamer Othmana University of California Davis Comprehensive Cancer Center, Sacramento, CA, USA

Benjamin N. Moskoffa University of California Davis Comprehensive Cancer Center, Sacramento, CA, USA

Naseem Esteghamata University of California Davis Comprehensive Cancer Center, Sacramento, CA, USA

Rasmus T. Hoegb Internal Medicine, Hematology and Oncology Department, University of California Davis School of Medicine, Sacramento, CA, USA

Aaron S. Rosenberga University of California Davis Comprehensive Cancer Center, Sacramento, CA, USA

https://orcid.org/0000-0003-0714-734X

Brian A. Jonasb Internal Medicine, Hematology and Oncology Department, University of California Davis School of Medicine, Sacramento, CA, USA

https://orcid.org/0000-0002-4921-5809

Mehrdad Abedib Internal Medicine, Hematology and Oncology Department, University of California Davis School of Medicine, Sacramento, CA, USA

Carol Richmana University of California Davis Comprehensive Cancer Center, Sacramento, CA, USA

Joseph M. Tuscanoa University of California Davis Comprehensive Cancer Center, Sacramento, CA, USACorrespondence[email protected]

show all

Click to increase image sizeClick to decrease image size

Disclosure statement

Aaron Rosenberg served as an advisor for adaptive Bio, and has participated in Speakers bureau for Takeda and Janssen.

Brian A Jonas served as a consultant/advisor for AbbVie, Amgen, BMS, Celgene, Genentech, GlycoMimetics, Jazz, Pfizer, Takeda, Tolero, and Treadwell, received travel reimbursement from AbbVie, and received research funding to his institution from 47, AbbVie, Accelerated Medical Diagnostics, Amgen, AROG, Celgene, Daiichi Sankyo, F. Hoffmann-La Roche, Forma, Genentech/Roche, Gilead, GlycoMimetics, Hanmi, Immune-Onc, Incyte, Jazz, Loxo Oncology, LP Therapeutics, Pfizer, Pharmacyclics, Sigma Tau, and Treadwell.

Mehrdad Abedi served as an advisor for Celgene and participated in Speakers Bureaus for BMS, Gilead, Seattle genetics, and Abbvie.

Joseph M Tuscano received research support from Genentech, Pharmacyclics, AbbVie, BMS, Acrotech, Seattle Genetics, and Takeda.

The remaining authors have no conflicts of interest to disclose.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Allogeneic hematopoietic cell transplantation using non-myeloablative ATG/TLI conditioning for lymphomas

Information for

Open access

Opportunities

Help and information

Allogeneic hematopoietic cell transplantation using non-myeloablative ATG/TLI conditioning for lymphomas

Disclosure statement

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature